[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20171573T1 - Solid form of dihydro-pyrido-oxazine derivative - Google Patents

Solid form of dihydro-pyrido-oxazine derivative Download PDF

Info

Publication number
HRP20171573T1
HRP20171573T1 HRP20171573TT HRP20171573T HRP20171573T1 HR P20171573 T1 HRP20171573 T1 HR P20171573T1 HR P20171573T T HRP20171573T T HR P20171573TT HR P20171573 T HRP20171573 T HR P20171573T HR P20171573 T1 HRP20171573 T1 HR P20171573T1
Authority
HR
Croatia
Prior art keywords
form according
anhydrous crystalline
crystalline form
therapeutically effective
pyrido
Prior art date
Application number
HRP20171573TT
Other languages
Croatian (hr)
Inventor
Konstanze Hurth
Christoph KALIS
Karen KAMMERTOENS
Nicolas Soldermann
Frédéric Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13824177.3A external-priority patent/EP2928896B1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20171573T1 publication Critical patent/HRP20171573T1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (8)

1. Bezvodni kristalni oblik, naznačen time, da je to bezvodni kristalni oblik od (1,1-diokso-heksahidro-1lambda*6*-tiopiran-4-il)-{(S)-3-[1-(6-metoksi-5-metil-piridin-3-il)-2,3-dihidro-1H-pirido[3,4-b][1,4]oksazin-7-iloksi]-pirolidin-1-il}-metanona. 1. Anhydrous crystalline form, indicated by the fact that it is an anhydrous crystalline form of (1,1-dioxo-hexahydro-1lambda*6*-thiopyran-4-yl)-{(S)-3-[1-(6- methoxy-5-methyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-methanone. 2. Bezvodni kristalni oblik prema zahtjevu 1, naznačen time, da njegov uzorak difrakcije praha X-zraka obuhvaća sljedeće vršne vrijednosti s danim kutom refrakcije pod sljedećim stupnjevima 2-theta (θ) ± 0,2 stupnja: 9,1, 10,2, 11,9, 13,0, 17,1, 17,7, 18,7, 20,3, 20,8, 26,0, 26,7, 23,2, 24,1, 24,8, 29,3, 27,4 i 21,4.2. An anhydrous crystalline form according to claim 1, characterized in that its X-ray powder diffraction pattern comprises the following peak values with a given angle of refraction under the following degrees of 2-theta (θ) ± 0.2 degrees: 9.1, 10.2 , 11.9, 13.0, 17.1, 17.7, 18.7, 20.3, 20.8, 26.0, 26.7, 23.2, 24.1, 24.8, 29 ,3, 27.4 and 21.4. 3. Bezvodni kristalni oblik prema zahtjevu 1, naznačen time, da ima spektar difrakcije X-zraka, koji je prikazan na Slici 1.3. The anhydrous crystalline form according to claim 1, characterized in that it has an X-ray diffraction spectrum, which is shown in Figure 1. 4. Bezvodni kristalni oblik prema zahtjevu 1, naznačen time, da ima dijagram diferencijalne skenirajuće kalorimetrije, koji je prikazan na Slici 2. 4. An anhydrous crystalline form according to claim 1, characterized in that it has a diagram of differential scanning calorimetry, which is shown in Figure 2. 5. Oblik prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se upotrebljava kao farmaceutsko sredstvo. 5. The form according to any one of claims 1 to 4, characterized in that it is used as a pharmaceutical agent. 6. Kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu oblika u skladu s bilo kojim od zahtjeva 1 do 4, i jedno ili više terapeutski djelotvornih tvari. 6. A combination, characterized in that it comprises a therapeutically effective amount of the form according to any one of claims 1 to 4, and one or more therapeutically effective substances. 7. Oblik prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se upotrebljava u liječenju bolesti odnosno poremećaja, posredovanih putem djelovanja enzima PI3K, poželjno putem djelovanja izoformnog enzima PI3Kδ. 7. The form according to any one of claims 1 to 4, characterized in that it is used in the treatment of diseases or disorders, mediated through the action of the PI3K enzyme, preferably through the action of the PI3Kδ isoform enzyme. 8. Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu oblika u skladu s bilo kojim od zahtjeva 1 do 4, te jedan ili više farmaceutski prikladnih nosača. 8. A pharmaceutical composition, characterized in that it comprises a therapeutically effective amount of the form according to any one of claims 1 to 4, and one or more pharmaceutically suitable carriers.
HRP20171573TT 2012-11-26 2017-10-17 Solid form of dihydro-pyrido-oxazine derivative HRP20171573T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
EP13824177.3A EP2928896B1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative
PCT/IB2013/060412 WO2014102630A1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative

Publications (1)

Publication Number Publication Date
HRP20171573T1 true HRP20171573T1 (en) 2017-11-17

Family

ID=54198861

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171573TT HRP20171573T1 (en) 2012-11-26 2017-10-17 Solid form of dihydro-pyrido-oxazine derivative

Country Status (8)

Country Link
JP (1) JP6310474B2 (en)
EA (1) EA028031B1 (en)
ES (1) ES2643902T3 (en)
HR (1) HRP20171573T1 (en)
HU (1) HUE036665T2 (en)
LT (1) LT2928896T (en)
MA (1) MA38100A1 (en)
SI (1) SI2928896T1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010027002A1 (en) * 2008-09-05 2012-02-02 塩野義製薬株式会社 Fused morpholine derivative having PI3K inhibitory activity
PL2794600T3 (en) * 2011-12-22 2018-06-29 Novartis Ag 2,3-Dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (PI3K) inhibitors for the treatment of e.g. rheumatoid arthritis

Also Published As

Publication number Publication date
JP6310474B2 (en) 2018-04-11
EA201591023A1 (en) 2015-09-30
ES2643902T3 (en) 2017-11-27
SI2928896T1 (en) 2017-10-30
EA028031B1 (en) 2017-09-29
LT2928896T (en) 2017-09-25
JP2016502531A (en) 2016-01-28
MA38100A1 (en) 2017-12-29
HUE036665T2 (en) 2018-07-30

Similar Documents

Publication Publication Date Title
BR112015015468B8 (en) COMPOUND AND PHARMACEUTICAL COMPOSITION
BR112015021888A8 (en) dna-pk inhibitors, their uses and pharmaceutical composition
IN2012DN06720A (en)
WO2013184876A8 (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
BR112013013167A8 (en) bromodomain inhibitors and their uses
CL2008001632A1 (en) Compounds derived from substituted benzoylamino-indan-2-carboxylic acids, inhibitors of the cxcr5 receptor; pharmaceutical composition; and its use in the treatment of inflammatory physiological effects, such as rheumatoid arthritis and asthma.
BR112016011484A2 (en) IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY
CL2014001664A1 (en) Compounds derived from 2 - ([1,4] dioxan-2-ylmethoxy) -6,7-dihydropyrimido [6,1-a] isoquinolin-4-one, gpr84 receptor antagonists; pharmaceutical composition; method of treatment or prophylaxis; and use in the treatment or prophylaxis of inflammatory conditions such as rheumatoid arthritis, vasculitis, asthma and psoriasis, among others.
CL2007002708A1 (en) COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS.
CR20130339A (en) NEW HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
PA8790401A1 (en) SULFONAMIDS AS TRPM8 MODULATORS
CL2011000668A1 (en) Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
IN2014DN09352A (en)
PE20121617A1 (en) OXAZINE DERIVATIVES AS BACE INHIBITORS
UY32427A (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
IN2014DN09348A (en)
CL2014002386A1 (en) Phospinosinoside 3 kinase inhibitor compound in solid crystalline anhydrous form; preparation procedure; pharmaceutical composition; and use in the treatment or prevention of diseases such as epoc, asthma, among others.
CL2014001838A1 (en) Compounds derived from fluormethyl-5,6-dihydro-4h- [1,3] oxazin-2-ylamine, as bace1 inhibitors; its process of obtaining; pharmaceutical composition that contains them; and its use for the therapeutic and / or prophylactic treatment of Alzheimer's disease, amyotrophic lateral sclerosis, cancer, cardiovascular diseases and gastrointestinal diseases, among others.
CO6852073A2 (en) Trpm8 antagonists and their use in treatments
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
NI201600047A (en) HAVE CYCLIC CARBOXAMIDES AND USES OF THE SAME
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX2015001657A (en) Lpar - substituted cyanopyrazole compounds.